(NASDAQ: TXG) 10x Genomics's forecast annual revenue growth rate of 34.58% is forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 21.14%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.33%.
10x Genomics's revenue in 2023 is $516,409,000.On average, 5 Wall Street analysts forecast TXG's revenue for 2023 to be $74,582,709,453, with the lowest TXG revenue forecast at $69,878,355,863, and the highest TXG revenue forecast at $78,500,100,972. On average, 2 Wall Street analysts forecast TXG's revenue for 2024 to be $91,925,867,690, with the lowest TXG revenue forecast at $81,513,212,856, and the highest TXG revenue forecast at $102,338,637,880.
In 2025, TXG is forecast to generate $160,345,540,560 in revenue, with the lowest revenue forecast at $160,345,540,560 and the highest revenue forecast at $160,345,540,560.